Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

HIATL1 Inhibitors

HIATL1 inhibitors are a class of chemical compounds that function by specifically targeting the HIATL1 protein. HIATL1, or "Histidine Ammonia-Lyase Transmembrane-like 1," is a protein that plays a role in certain biochemical pathways within cells, particularly those involving the modulation of proteolytic processes. These inhibitors typically work by binding to active sites or allosteric sites on the HIATL1 protein, thereby preventing its normal activity. The inhibition of HIATL1 can lead to alterations in various downstream biological mechanisms that are influenced by the protein's regular functioning. HIATL1 itself is structurally characterized by transmembrane domains, suggesting it has a role in cellular processes related to membrane function and the transport of molecular signals. Thus, inhibitors designed to interact with HIATL1 tend to have chemical structures optimized to disrupt these interactions, either by physically blocking key binding sites or inducing conformational changes in the protein.

The design of HIATL1 inhibitors involves a deep understanding of the protein's three-dimensional structure, particularly its catalytic domains, transmembrane regions, and associated regulatory elements. Researchers often employ techniques such as X-ray crystallography, molecular docking, and computational chemistry to predict how potential inhibitors might interact with HIATL1. These inhibitors may be derived from a variety of chemical classes, such as small organic molecules, peptides, or synthetic analogs, each tailored to fit within or near the functional domains of the protein. Beyond their specific binding characteristics, these inhibitors can be further modified for optimal stability, solubility, and specificity to HIATL1, ensuring that their interaction with other proteins or cellular components is minimized. Understanding the precise structure-activity relationships (SAR) of these inhibitors is essential for the development of effective compounds that can robustly modulate HIATL1 activity at the molecular level.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin inhibits PI3K, which can impact cellular processes. Its action may indirectly affect HIATL1's activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002, a PI3K inhibitor, might alter pathways that are associated with HIATL1, thereby modulating its function.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is a MEK inhibitor that might influence HIATL1's functionality via MAPK signaling pathway modulation.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 inhibits JNK, which could modify pathways where HIATL1 is operational.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

By inhibiting vacuolar ATPases, Bafilomycin A1 may have implications on HIATL1-related cellular processes.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

As a ROCK inhibitor, Y-27632 can potentially influence pathways that are relevant to HIATL1's functions.

Tyrphostin AG 1478

175178-82-2sc-200613
sc-200613A
5 mg
25 mg
$96.00
$421.00
16
(1)

AG1478's inhibitory action on EGFR signaling may have indirect effects on HIATL1's associated pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 inhibits P38 MAPK, potentially affecting signaling processes relevant to HIATL1.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin, as an mTOR inhibitor, might indirectly modulate HIATL1 functions by altering mTOR signaling pathways.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

Staurosporine inhibits a range of kinases which could indirectly modulate pathways associated with HIATL1.